Basal Cell Carcinoma Drug Pipeline: 20 Assets by Phase

How many basal cell carcinoma drugs are in each phase of development?

Douglas Insights counts 1 basal cell carcinoma candidates in Phase III, 5.0% of the 20 assets in development; Phase II holds 11 and Phase I holds 8.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each basal cell carcinoma asset appears in exactly one row. The 46 trials still recruiting or running carry 43% of the 108 registered trials in scope.

Which approved basal cell carcinoma medicines are still in trials?

1 medicines already on the market are still being tested in basal cell carcinoma Phase IV trials; Sonidegib Phosphate has the most, with 1 registered trials.

Post-approval basal cell carcinoma trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many basal cell carcinoma trials are recruiting patients now?

28 basal cell carcinoma trials are recruiting patients and 4 more have not started recruiting yet, out of 108 interventional trials in scope; together they make up 30% of the trial base.

Terminated, suspended and withdrawn basal cell carcinoma trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the basal cell carcinoma pipeline?

Regeneron Pharmaceuticals leads the basal cell carcinoma pipeline with 3 candidates; the top 5 sponsors hold 50% of the 20 assets, and 15 sponsors run at least one.

Industry sponsors lead 49 of the 108 basal cell carcinoma trials (45%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the basal cell carcinoma pipeline?

Mechanism and drug-type classification for the 20 basal cell carcinoma candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What basal cell carcinoma trial readouts are coming next?

1 basal cell carcinoma candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many basal cell carcinoma readouts fall in each quarter?

1 basal cell carcinoma candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 1, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most basal cell carcinoma trials?

United States hosts the most basal cell carcinoma trials, with sites in 66 of the 108 studies (61%); trials in scope run in 31 countries in all.

A multinational basal cell carcinoma trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are basal cell carcinoma drugs being tested?

66 of the 108 basal cell carcinoma trials (61%) have a site in the United States, 39 (36%) in Europe and 2 (1.9%) in China; 18 of the 20 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational basal cell carcinoma trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the basal cell carcinoma pipeline since the last update?

This is the first edition of the basal cell carcinoma pipeline count, dated 4 Oct 2026. The next refresh is due by 2 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the basal cell carcinoma pipeline?

Douglas Insights read 108 interventional trials registered on ClinicalTrials.gov for the conditions "carcinoma, basal cell", "basal cell carcinoma" and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 20 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the basal cell carcinoma pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage